Dr. Kline is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5841 S Maryland Ave
# MC2115
Chicago, IL 60637Phone+1 773-702-5550Fax+1 773-702-3163
Summary
- Dr. Justin Kline is an oncologist in Chicago, IL and is affiliated with University of Chicago Medical Center. He received his medical degree from University of Chicago Pritzker School of Medicine and has been in practice 16 years. He specializes in hematologic oncology and is experienced in hematologic oncology and stem cell transplantation.
Education & Training
- University of ChicagoFellowship, Hematology and Medical Oncology, 2004 - 2007
- University of ChicagoResidency, Internal Medicine, 2001 - 2004
- University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2001
Certifications & Licensure
- IL State Medical License 2007 - 2026
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Stem Cell Transplantation for Patients With Multiple Myeloma Start of enrollment: 2011 Jul 12
- Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL) Start of enrollment: 2023 Aug 02
- Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma Start of enrollment: 2019 Aug 29
- Join now to see all
Publications & Presentations
PubMed
- Targeting DTX2/UFD1-mediated FTO degradation to regulate antitumor immunity.Yan-Hong Cui, Jiangbo Wei, Hao Fan, Wenlong Li, Lijie Zhao
Proceedings of the National Academy of Sciences of the United States of America. 2024-12-17 - Optimization of older adults by a geriatric assessment-guided multidisciplinary clinic before CAR T-cell therapy.Samuel J Yates, John F Cursio, Andrew Artz, Keriann Kordas, Michael R Bishop
Blood Advances. 2024-07-23 - FLT3 inhibitor maintenance after allogeneic stem cell transplantation in-mutated acute myeloid leukemia (AML) patients.Gong He, Erika Belmont, Theodore Karrison, Wendy Stock, James L LaBelle
Annals of Translational Medicine. 2024-06-10
Journal Articles
- CD8α+ Dendritic Cells Dictate Leukemia-Specific CD8+ T Cell FatesJustin Kline, MD, The Journal of Immunology
- CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s LymphomaMark P Chao, Sonali M Smith, Ranjana Advani, Ian Flinn, Ravindra Majeti, Nancy L Bartlett, Leslie Popplewell, Justin Kline, Nilanjan Ghosh, Ann LaCasce, The New England Journal of Medicine
Abstracts/Posters
- Beyond PD-1: Investigating the Therapeutic Potential of TIGIT Blockade in DLBCLJustin Kline, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Integrative Immunogenomic Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Identifies Four Molecular Subtypes with Distinct Immune LandscapesJustin Kline, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDSJustin Kline, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 CheckMate 436 Trial2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Emerging Role of Immune Checkpoint Blockade in the Treatment of Refractory/Relapsed Hodgkin and Non-Hodgkin Lymphoma60th American Society of Hematology Annual Meeting - 11/30/2018
Press Mentions
- ASCO Annual Meeting Returns to Chicago, Celebrates New Progress in CancerJune 15th, 2022
- New Analysis of the Tumor Microenvironment Reveals 3 Subtypes in Large B-cell Lymphoma of the BrainSeptember 28th, 2020
- ‘Encouraging’ Responses Seen with Durvalumab plus R-CHOP in DLBCLJune 17th, 2019
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: